ImmunoMod is addressing a large and rapidly growing market need with a strong portfolio of products, a highly skilled scientific team, and a seasoned investor and operator. We are currently assembling our Scientific and Business Advisory Boards, and are actively expanding our team with individuals who bring a wealth of experience and contacts from early stage drug development companies, large pharmaceutical companies, medical universities, and private investment companies. We are passionate and fully committed to our cause and see tremendous potential for us to create medical and investment value in the marketplace.
Our primary efforts in the next 6-12 months will be to push forward our current trials of our most developed clinical candidates, and begin larger Phase 2 and Phase 3 trials. Our first round of funding (raised early this year) will help us complete current trials on our first candidates. We will be seeking additional funding and partnership options to expand trials on existing drugs, conduct preliminary trials on new drugs, and to identify and recruit additions to our management team. These options include FDA and other Federal grants, investments from large pharmaceutical companies, and venture capital funding.
